<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03035422</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00862-49</org_study_id>
    <nct_id>NCT03035422</nct_id>
  </id_info>
  <brief_title>Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia</brief_title>
  <acronym>SET-HAPLO</acronym>
  <official_title>Sequential Chemotherapy Prior to Reduced Intensity Conditioning: Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Training, Education, and Research in Hematology, Immunology, and Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association for Training, Education, and Research in Hematology, Immunology, and Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option&#xD;
      with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple&#xD;
      relapses after chemotherapy. However, all patients with an indication of allo-HSC can not&#xD;
      benefit because of two limitations: the toxicity of the treatment and graft shortage&#xD;
      available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to evaluate the efficacy and safety of the combination of an SET followed by&#xD;
      haploidentical transplant with post-transplant immune modulation by prophylactic DLI in&#xD;
      patients with refractory acute myeloid leukemia or relapsed. The main objective is to assess&#xD;
      overall survival at 2 years in these patients.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To evaluate the efficacy of this therapeutic strategy in terms of remission of disease,&#xD;
           incidence of relapse and relapse-free survival&#xD;
&#xD;
        2. To evaluate the non-relapse mortality&#xD;
&#xD;
        3. To evaluate the incidence of acute and chronic graft against host disease (GVHD)&#xD;
&#xD;
        4. To assess the feasibility of prophylactic injections of donor lymphocytes (pDLI)&#xD;
&#xD;
        5. To analyze the post-transplant immune reconstitution&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. partial or complete remission rate by standard criteria at 90 days and then 6, 12 and 24&#xD;
           months after transplantation.&#xD;
&#xD;
           Relapse incidence and death related to the disease 90 days 6, 12 and 24 months after&#xD;
           transplantation Leukemia-free survival at 1 year and 2 years after transplantation&#xD;
&#xD;
        2. Cumulative incidence of death not related to relapse at 90 days, 1 year and 2 years&#xD;
           after transplantation&#xD;
&#xD;
        3. Cumulative incidence of acute and chronic graft against host disease (GVHD)&#xD;
&#xD;
        4. Number of patients for whom pDLI was possible and number of pDLI / patient; incidence,&#xD;
           severity and treatment of possible secondary GVHD in these patients&#xD;
&#xD;
        5. Study of immune reconstitution post-transplant in the peripheral blood 30, 90 and 180&#xD;
           days after transplantation (CD4 lymphocyte levels, CD8, T regulators, Natural Killer&#xD;
           cells and B cells)&#xD;
&#xD;
      Methodology, experimental design:&#xD;
&#xD;
      Multicenter study in routine care, prospective&#xD;
&#xD;
      All patients will receive, as part of the marketing authorization of the products used, the&#xD;
      following regimen:&#xD;
&#xD;
      1- sequential Packaging (SET):&#xD;
&#xD;
        1. sequential chemotherapy:&#xD;
&#xD;
             -  Thiotepa 5 mg / kg / day for 1 day (D-13)&#xD;
&#xD;
             -  Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)&#xD;
&#xD;
             -  Etoposide 100 mg / m² / day for 4 days (J-12 to J-9)&#xD;
&#xD;
        2. Rest days J-8 and J-6&#xD;
&#xD;
        3. Reduced-intensity conditioning (RIC)&#xD;
&#xD;
             -  Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)&#xD;
&#xD;
             -  Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)&#xD;
&#xD;
             -  Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)&#xD;
&#xD;
                2 Graft transfusion: the day D0. A graft of peripheral stem cells is preferred.&#xD;
&#xD;
                3- Prevention of GVHD:&#xD;
&#xD;
             -  Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5&#xD;
&#xD;
             -  Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)&#xD;
&#xD;
             -  Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)&#xD;
&#xD;
                4- Care supports: according to the protocols of each center&#xD;
&#xD;
                5- lymphocyte injection of prophylactic donor (pDLI): according to the protocols of&#xD;
                each center. The following scheme is proposed:&#xD;
&#xD;
             -  In the absence of clinical contraindication(GVHD), tapering MMF between days D + 35&#xD;
                and D + 56, then tapering CSA between D + 62 and D + 90&#xD;
&#xD;
             -  pDLI: 3 injections from the D + 120 in patients who discontinued immunosuppressive&#xD;
                therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade&gt; II.&#xD;
&#xD;
                6. Feedback: at baseline and 1, 3, 6, 12 and 24 months after transplant&#xD;
                (engraftment, disease response, immune reconstitution, chimerism, GVHD, infection,&#xD;
                quality of life).&#xD;
&#xD;
      The treatments evaluated in this strategy are all used in the usual care of patients and&#xD;
      follow-up will not be changed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>The aim is to describe the efficacy of the combination of a SET followed by haploidentical transplant with post-transplant immune modulation by pDLI in patients with AML.&#xD;
The main objective is to assess overall survival at 2 years in these patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial or complete remission rate by standard criteria Relapse incidence and death related to the disease</measure>
    <time_frame>90 days and then 6, 12 and 24 months after transplantation</time_frame>
    <description>To evaluate the efficacy of this therapeutic strategy in terms of remission of disease, incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death not related to relapse</measure>
    <time_frame>90 days and then 12 and 24 months after transplantation</time_frame>
    <description>Assess not related to relapse mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute and chronic graft against host disease (GVHD)</measure>
    <time_frame>100 days and then 12 and 24 months after transplantation</time_frame>
    <description>To evaluate the incidence of acute and chronic graft against host disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients for whom pDLI was possible.</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>Assess the feasibility of prophylactic injections of donor lymphocytes (pDLI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of immune reconstitution post-transplant in the peripheral blood will be used:CD4 lymphocyte levels, CD8, T regulators, Natural Killer cells and B cells</measure>
    <time_frame>90 days and then 6, 12 and 24 months after transplantation</time_frame>
    <description>Study the post-transplant immune reconstitution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>90 days and then 6, 12 and 24 months after transplantation</time_frame>
    <description>Relapse-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pDLI / patient; incidence, severity and treatment of possible secondary GVHD in these patients</measure>
    <time_frame>90 days and then 6, 12 and 24 months after transplantation</time_frame>
    <description>Assess the feasibility of prophylactic injections of donor lymphocytes (pDLI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with primary refractory acute myeloid leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential Packaging (SET)</intervention_name>
    <description>Sequential chemotherapy:&#xD;
Thiotepa 5 mg / kg / day for 1 day (D-13)&#xD;
Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)&#xD;
Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)&#xD;
Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)&#xD;
Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)&#xD;
Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)</description>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transfusion graft</intervention_name>
    <description>Graft of peripheral stem cells is preferred at D0</description>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevention of GVHD</intervention_name>
    <description>Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5&#xD;
Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)&#xD;
Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)</description>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Care supports</intervention_name>
    <description>According to the protocols of each center</description>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphocyte injection of prophylactic donor (PDLI)</intervention_name>
    <description>According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90&#xD;
- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade&gt; II</description>
    <arm_group_label>Patients with primary refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of acute myeloid leukemia after primary induction&#xD;
             treatment failure (persistent leukemia after 2 cycles of induction chemotherapy)&#xD;
&#xD;
          -  Patient age ≥ 18 to &lt;60 years&#xD;
&#xD;
          -  Cardiac ejection fraction of the left ventricle ≥ 45%&#xD;
&#xD;
          -  Lung function - free diffusion capacity for carbon monoxide ≥ 50% of predicted value&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 ml / min depending on the CKD-EPI formula&#xD;
&#xD;
          -  Availability of an HLA haploidentical donor in the family&#xD;
&#xD;
          -  Collection of non-opposition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled invasion of CNS&#xD;
&#xD;
          -  Availability of an HLA identical family donor who agreed to donate hematopoietic stem&#xD;
             cells OR non-related donor HLA-compatible 10/10 on HLA-A alleles, B, C, and DRB1 DQB1&#xD;
             available and ready to give in 4 weeks to make a decision allograft&#xD;
&#xD;
          -  Presence in the patient HLA-specific antibodies directed against an antigen HLA&#xD;
             haploidentical donor family&#xD;
&#xD;
          -  Karnofsky score &lt;70%&#xD;
&#xD;
          -  Patient HIV positive&#xD;
&#xD;
          -  Hepatitis B or C or chronic active&#xD;
&#xD;
          -  Uncontrolled infection at the time of start packing&#xD;
&#xD;
          -  Contraindication to the use of treatments provided by the Protocol&#xD;
&#xD;
          -  Previous history of allo-HSC&#xD;
&#xD;
          -  No beneficiary of a social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service d'hématologie Clinique Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogenic cell stem transplant, Sequential chemotherapy Haploidentical transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

